<DOC>
	<DOC>NCT02808442</DOC>
	<brief_summary>This study aims at evaluating the safety and ability of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) ahead of planned allogeneic hematopoietic stem cell transplantation (allo-HSCT).</brief_summary>
	<brief_title>Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Patient with relapsed or refractory CD19positive Bacute lymphoblastic leukaemia (BALL) 1. who have exhausted available treatment options 2. eligible for alloHSCT with suitable donor available Estimated life expectancy â‰¥ 12 weeks Considered medically fit for alloHSCT Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2 Burkitt leukemia CD19negative Bcell leukemia Uncontrolled Central Nervous System (CNS) leukemia Active acute or chronic GraftversusHost Disease (GvHD)</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>